1 / 50

Pharmacology of Antidepressants

Pharmacology of Antidepressants. Dr Andrew P Mallon. Classes of Antidepressants Tricyclic-tertiary amines. amitriptyline (Elavil) imipramine (Tofranil) doxepin (Sinequan) clomipramine (Anafranil) trimipramine (Surmontil). Classes of Antidepressants Tricyclic-secondary amines.

jatherton
Download Presentation

Pharmacology of Antidepressants

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Pharmacology of Antidepressants Dr Andrew P Mallon

  2. Classes of AntidepressantsTricyclic-tertiary amines • amitriptyline (Elavil) • imipramine (Tofranil) • doxepin (Sinequan) • clomipramine (Anafranil) • trimipramine (Surmontil)

  3. Classes of AntidepressantsTricyclic-secondary amines • desipramine (Norpramin) • nortriptyline (Pamelor) • protriptyline (Vivactyl) • amoxapine (Ascendin)

  4. Classes of AntidepressantsAtypical (non-tricyclic) • maprotiline (Ludiomil) • trazodone (Desyrel) • bupropion (Wellbutrin) • venlafaxine (Effexor) • nefazodone (Serzone) • mirtazapine (Remeron)

  5. Classes of AntidepressantsSpecific serotonin reuptake inhibitors (SSRIs) • fluoxetine (Prozac) • sertraline (Zoloft) • paroxetine (Paxil) • fluvoxamine (Luvox) • citalopram (Celexa)

  6. Classes of AntidepressantsMonoamine oxidase inhibitors (MAOIs) • phenelzine (Nardil) • isocarboxazid (Marplan) • tranylcypromine (Parnate) • selegiline (Deprenyl)

  7. Classes of AntidepressantsPsychostimulants • methylphenidate (Ritalin) • dextro-amphetamine (Dexedrine) • magnesium pemoline (Cylert) • dex + amphetamine (Adderall) • methamphetamine (Desoxyn) • modafinil (Provigil)

  8. Evaluation of the depressed patientGoals of the evaluation • Establish a diagnosis • Identify specific target symptoms • Consider comorbidity • Quantify depression and/or specific symptoms

  9. Evaluation of the depressed patient • Obtain psychiatric history and perform mental status exam • Identify and r/o underlying medical problems • Physical exam in the past year

  10. Evaluation of the depressed patient • Optional exams: • Laboratory • Neurological exam • Dexamethasone suppression test • TRH test

  11. Is an antidepressant indicated? • The decision to treat a patient with antidepressants should be based on the following: • Severity of symptoms and ability to identify target symptoms • Impairment of functioning • Patient’s view of medication • Not necessarily the specific diagnosis

  12. Predictors of antidepressant response. • Acute onset • Severe depressive symptoms • Positive previous response to medication • Patient’s willingness to accept medication as an aid to successful treatment

  13. How to start antidepressants? • Start low to assess tolerance of side effects • Increase dosage rapidly as tolerated • Maintain typical dose for at least 4 to 8 weeks

  14. Most common reasons antidepressants fail • Dosage too low • Duration of trial to short • Poor compliance • Intolerable side effects

  15. What is an adequate trial? • Adequate dose: • 5 mg/kg/d • Nortriptyline 100 to 150/d (therapeutic window) • Fluoxetine 20 mg/d • Adequate duration: • 4 – 8 weeks

  16. Indications for serum levels • Unequivocally useful for: • Patients who are not responding to usual doses • Patients who are at increased risk for toxicity, e.g. cardiac patients • May be useful for: • Patients where prompt response is critical • Determining compliance and metabolic availability

  17. Therapeutic Blood Levelsfor antidepressants • Known: • imipramine • desipramine • nortriptyline • Possibly known: • amitriptyline • Under assessment: • All other antidepressants

  18. How Antidepressants Work • Most of the important clinical actions of antidepressant drugs cannot be fully accounted for on the basis of “synaptic pharmacology”. • There are two important observations that contribute to this rationale.

  19. How Antidepressants Work • Many drugs require long term administration to be effective. • Drugs of abuse require repeated administration to produce tolerance and physical dependence.

  20. How Antidepressants Work • Clinical effects would appear to result from the slow onset adaptive changes that occur within neurons, not within the synapse. • That is, activation of intraneuronal messenger pathway and regulation of neural gene expression play a central role. (drug-induced neural plasticity).

  21. “Synaptic Pharmacology”of antidepressants • Acute: • Block reuptake or degradation of monoamines and post-synaptic alpha-1 receptor. • Chronic: • Down regulation of the post-synaptic receptors • Alteration of second messenger systems • Alteration of protein synthesis.

  22. After Dosing Antidepressants(days) Synaptic effects: hours to days Side effects: hours to days Therapeutic effect: 1 to 6 weeks Series 1

  23. Pharmacokinetics of Antidepressants • Absorption is rapid • Metabolism: extensive 1st pass • Oxidation, hydroxylation, demethylation • 5% = “slow acetylators” • Protein bound: 90 – 95%

  24. Antidepressant half-lives (hrs)

  25. Cardiac Side-effectsof tricyclic antidepressants • Cardiac conduction delay • Anti-arrhythmic at therapeutic doses • Arrhythmigenic at toxic doses • Minimal effects on cardiac output

  26. Cardiac Side-effectsof tricyclic antidepressants • Monitoring EKG parameters: • QTc = 450 msec • PR = 210 msec • QRS - >30% above baseline

  27. How to choose an antidepressant • Rationale should be based on side effects, not efficacy • The SSRIs, secondary amines, and atypical antidepressants, are generally better choices. • Why?

  28. Norepinephrine uptake blockadePossible clinical consequences • Tremors • Tachycardia

  29. Norepinephrine uptake blockade (potency)

  30. Serotonin reuptake blockadePossible clinical consequences • Gastrointestinal disturbances • Anxiety (dose – dependent) • Sexual dysfunction

  31. Serotonin uptake blockade(potency)

  32. Blocking selectivity5-HT vs. NE

  33. Dopaminergic uptake blockadePossible clinical consequences • Psychomotor activation • Antiparkinsonian effects • Psychoses • Increased attention/concentration

  34. Dopamine uptake blockade(potency)

  35. Histamine H1 blockadePossible clinical consequences • Sedation, drowsiness • Weight gain • hypotension

  36. Histamine H1 receptor blockade(affinity)

  37. Muscarinic receptor blockadepossible clinical consequences • Blurred vision • Dry mouth • Sinus tachycardia • Constipation • Urinary retention • Memory dysfunction

  38. Muscarinic receptor blockade(affinity)

  39. alpha – 1 receptor blockadepossible clinical consequences • Postural hypotension • Reflex tachycardia • Dizziness

  40. alpha-1 receptor blockade (affinity)

  41. imipramine (Tofranil)receptor affinities

  42. fluoxetine (Prozac)receptor affinities

More Related